-
May 16, 2024 | 
onlinelibrary.wiley.com | Helena A. Yu |Jun Mo |Lynne M. Bird |Sunita Sridhar
LETTER TO THE EDITOR Concurrent rhabdomyosarcoma and neuroblastoma in an infant with Costello syndrome Helena Yu, Corresponding Author Helena Yu Division of Hematology/Oncology, Department of Pediatrics, Rady Children's Hospital-San Diego, San Diego, California, USA Department of Pediatrics, University of California San Diego, La Jolla, California, USA Correspondence Helena Yu, Division of Hematology/Oncology, Department of Pediatrics, Rady Children's Hospital-San Diego, San Diego, CA, USA.
-
Oct 6, 2023 | 
onclive.com | Helena A. Yu
Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01 Background EGFR-activating mutations occur in 14% to 38% of patients with NSCLC Salvage therapies after EGFR TKI therapy and platinum-based chemotherapy provide only limited and transient clinical benefit CNS metastases are common in this population, and therapies to ensure CNS control are needed A phase 1 study of HER3-DXd for advanced NSCLC demonstrated efficacy in...
-
Sep 10, 2023 | 
ascopubs.org | Helena A. Yu |James Yang |Martin Reck |Luis Paz-Ares
After tumor progression with EGFR TKI therapy and PBC in patients with EGFR -mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. A phase III trial in EGFR- mutated NSCLC after progression on an EGFR TKI is ongoing (HERTHENA-Lung02; ClinicalTrials.gov identifier: NCT05338970 ).
-
Sep 10, 2023 | 
brnw.ch | Helena A. Yu |James Yang |Martin Reck |Luis Paz-Ares
For patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small-cell lung cancer (NSCLC), initial treatment typically includes one or two EGFR tyrosine kinase inhibitor (TKI) regimens comprising either a third-generation EGFR TKI or a first- or second-generation EGFR TKI followed by a third-generation EGFR TKI when the EGFR T790M mutation is detected.1 After disease progression on EGFR TKI therapy, patients are usually treated with platinum-based chemotherapy (PBC; with...
-
Jun 22, 2023 | 
onclive.com | Helena A. Yu
Helena A. Yu, MD, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses findings from a phase 1 trial (NCT05194982) investigating the bispecific antibody-drug conjugate (ADC) BL-B01D1, which is directed against both HER3 and EGFR, in patients with locally advanced or metastatic solid tumors such as non–small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma, and head and neck squamous cell carcinoma.
-
May 8, 2023 | 
cancernetwork.com | Joshua K. Sabari |Helena A. Yu
Transcript:Joshua K. Sabari, MD: Helena, in line with using your best therapy first, now that these therapies are approved in the second-line setting, how do you see them moving to the frontline setting? Helena A. Yu, MD: Absolutely. We know that these work and we know they’re well tolerated, and they lead to good quality of life. And so, the next natural step is can we move it even earlier and think about first-line treatment? I’m really excited.
-
May 1, 2023 | 
cancernetwork.com | Joshua K. Sabari |Helena A. Yu
Transcript:Joshua K. Sabari, MD: Let’s jump into the data in a little bit more detail here for this patient population. So, with amivantamab [Rybrevant], again, 114 patients enrolled in cohort D of the CHRYSALIS study. We looked at a TKI [tyrosine kinase inhibitor] pre-treated patient population. This is in the comparator arm, 69 patients who received osimertinib [Tagrisso] at 80 mg. There were 91 patients in the IO [immuno-oncology] arm.
-
May 1, 2023 | 
cancernetwork.com | Joshua K. Sabari |Helena A. Yu
Transcript:Joshua K. Sabari, MD: When we did this real-world analysis comparing amivantamab [Rybrevant] to these other regimens across the board looking at PFS [progression-free survival], OS [overall survival], time to next treatment, amivantamab seemed to be better than any of these other types of regimens. What do you think about that data? How does that apply to your clinical practice? Helena A.
-
Apr 24, 2023 | 
cancernetwork.com | Joshua K. Sabari |Helena A. Yu
Transcript:Joshua K. Sabari, MD: Let’s jump into the data for the CHRYSALIS study. This was a dose-escalation phase 1 study for amivantamab, which is an EGFR and c-MET bispecific antibody. We looked at a specific cohort, cohort D, of patients with EGFR exon 20 insertion mutations. In this cohort, we enrolled 114 patients, and all patients are treated at the recommended phase 2 dose, either 1050 mg for patients weighing less than 80 kg, or for those weighing more than 80 kg, 1400 mg.
-
Apr 24, 2023 | 
cancernetwork.com | Joshua K. Sabari |Helena A. Yu
Transcript:Joshua K. Sabari, MD: This question led us to this study of amivantamab vs alternative real-world anti-cancer therapies in patients with advanced non–small cell lung cancer with EGFR exon 20 insertion mutations. What we did was we took patients from the CHRYSALIS study, cohort D, 114 patients, and we looked in large databases. In the United States, we used things like Flatiron Health, ConcertAI databases. We looked across Europe, including Germany and other countries. So, a large data set.
